Log In
Print this Print this

Evotaz, atazanavir/cobicistat

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionFixed-dose combination of atazanavir, an HIV protease inhibitor, and cobicistat, an inhibitor of cytochrome P450 3A (CYP3A)
Molecular Target HIV protease
Mechanism of ActionHIV protease inhibitor; Cytochrome P450 3A (CYP3A) inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV-1 infection in combination with other antiretroviral agents
Regulatory Designation
PartnerGilead Sciences Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today